Patent ID: 9365613
Filing Date: 2016-06-14
CPC Classification: A61K,A61P,C07K

Claim Text:
1. A method of inhibiting plasma kallikrein and/or factor XIa and/or factor XIIa in-a patient having a condition selected from the group consisting of cardiac infarction, an embolism, deep leg vein thrombosis, unstable angina, complications as a consequence of angioplasty, disseminated intravascular coagulation, septic shock, allergies, postgastrectomy syndrome, and adult respiratory distress syndrome, said method comprising administering to said patient a compound of formula I: wherein P1 is unsubstituted 4-amidinobenzylamine; and (1) P4 is unsubstituted benzylsulfonyl, (2) P4 is benzylsulfonyl substituted with 4-COON or 4-COOMe, (3) P4 is benzylsulfonyl substituted with 4-CN, (4) P4 is unsubstituted benzylsulfonyl, (5) P4 is benzylsulfonyl substituted with 3-CN, 3-aminomethyl, or 3-(Glut-NHCH wherein the sulfur atom of the benzylsulfonyl group of P4 is linked to the α-amino group of P3, the carbon atom of the carbonyl group of P3 is bonded to the α-amino group of P2 or, when P2 is hSer, to the β-amino group of P2, and